Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 37Thoracic 28CNS 18Sarcoma 5Other hematologic neoplasm 3Tumor-Agnostic 2Lymphoid 2Endocrine 2Plasma cell 1Other solid neoplasm 1Myeloid 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Neoplasms 1Neoplasm Metastasis 1

Interventions

Paclitaxel 26Carboplatin 25pembrolizumab 22Gemcitabine 22Nivolumab 20Cisplatin 15Bevacizumab 14Docetaxel 13Pemetrexed 12Ipilimumab 12Erlotinib Hydrochloride 12Capecitabine 12Fluorouracil 11Irinotecan 10Afatinib 10eribulin 9BI 6727 9130-nm albumin-bound paclitaxel 9Radiotherapy 8Magnetic Resonance Spectroscopy 8Leucovorin 8Everolimus 8Cyclophosphamide 8Albumin-Bound Paclitaxel 8olaparib 7Oxaliplatin 7lenvatinib 6avelumab 6Trastuzumab 6Cetuximab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Topotecan × Tumor-Agnostic × Clear all
NCT00382733 2013-07-22

Oral Topotecan to Treat Recurrent or Persistent Solid Tumors

Accelerated Community Oncology Research Network

Phase 1/2 Completed
26 enrolled 8 charts
Tumor-Agnostic

Neoplasms

NCT00611468 2011-08-22

Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors

Accelerated Community Oncology Research Network

Phase 1 Completed
29 enrolled 13 charts
Tumor-Agnostic

Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡